Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | ||
Ninlaro | Ixazomib | Multiple Myeloma (2nd-beyond) | Do not reimburse | Complete | ||
Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | ||
Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete |